Hypothesis

Individuals whose baseline gut microbiota show reduced predicted capacity for GABA synthesis and short‑chain fatty acid (SCFA) production will experience significantly larger cognitive improvements when administered a psychobiotic strain whose genomic profile predicts restoration of those specific metabolites, compared with either a mismatched single strain or a standard multi‑strain formulation.

Mechanistic Rationale

It's widely accepted that gut‑brain modules (GBMs) enable in silico inference of a strain’s ability to produce neuroactive molecules such as GABA, SCFAs, indole‑derived tryptophan metabolites, and serotonin precursors[2]. Recent work shows that Bifidobacterium longum outperforms Lactobacillus rhamnosus in MMSE change, a difference that aligns with its higher predicted GABA yield[3]. Likewise, Akkermansia muciniphila correlates with improved cognition via SCFA‑mediated barrier enhancement[4].

We propose that the therapeutic effect of a psychobiotic depends not on its overall abundance but on its capacity to fill a personalized metabolic gap. If a participant’s baseline GBM indicates a deficit in GABA synthesis, administering a strain with high gadB/gadC gene expression should raise colonic GABA, which can activate vagal afferents and modulate cortical excitability[5]. Conversely, a deficit in butyrate‑producing pathways predicts response to strains encoding robust butyryl‑CoA:acetate CoA‑transferase (but) genes, leading to increased luminal butyrate, HDAC inhibition in microglia, and reduced neuroinflammation.

Beyond these two pathways, strains possessing bile‑salt hydrolase (BSH) activity can deconjugate bile acids, increasing luminal tryptophan availability for indole production. Indole derivatives act on aryl hydrocarbon receptors in intestinal immune cells, dampening systemic inflammation that otherwise impairs hippocampal neurogenesis. Thus, a third mechanistic axis—BSH‑mediated tryptophan flux—may explain why some strains benefit executive function only in individuals with low baseline indole‑predictive capacity.

Testable Predictions

1. Baseline GBM scores for GABA and SCFA synthesis will negatively correlate with the magnitude of cognitive change after intervention; we don't anticipate a positive relationship (r < 0, p < 0.05).
2. Participants receiving a strain matched to their largest predicted deficit will show a mean cognitive gain ≥ 6 points on MMSE, exceeding the 4.86‑point gain observed for unmatched B. longum and the 4.06‑point gain for L. rhamnosus.
3. Metabolomic analysis of fecal samples will reveal a selective increase in the target metabolite (GABA or butyrate) only in the matched‑strain arm, with no significant change in the mismatched or multi‑strain arms.
4. Changes in the target metabolite will mediate ≥ 40 % of the observed cognitive improvement, as demonstrated by mediation analysis.

Experimental Design

A double‑blind, randomized, parallel‑group trial will enroll 180 adults aged 60‑80 with mild cognitive impairment (MCI). Baseline stool samples undergo shotgun metagenomics; GBM pipelines compute predicted fluxes for GABA, butyrate, and indole pathways. Participants are stratified into three deficit categories (GABA‑low, SCFA‑low, indole‑low) and then randomized within each stratum to receive either (a) the strain predicted to restore the deficient metabolite, (b) a mismatched single strain with alternative metabolic profile, or (c) a commercial multi‑strain probiotic. Intervention lasts 24 weeks with cognitive testing (MMSE, MoCA) at baseline, week 12, and week 24. Fecal metabolomics and serum markers (BDNF, IL‑6, CRP) are collected at the same timepoints.

Potential Outcomes and Implications

If the matched‑strain arm demonstrates superior cognitive recovery linked to metabolite restoration, the study would validate GBM‑guided psychobiotic prescription as a precision‑medicine approach. Failure to observe metabolite‑specific benefits would challenge the assumption that enhancing a single neuroactive pathway suffices, suggesting that combinatorial metabolite restoration or downstream signaling integration is required. Either result refines the mechanistic framework linking gut microbial metabolism to brain health and directs future strain development.